Ranbaxy Fights Doc Bid In Nexium Pay-For-Delay Fight
By Aaron Vehling ( September 3, 2014, 2:26 PM EDT) -- Generic-drug maker Ranbaxy Inc. on Tuesday told a Massachusetts federal court it did not need to turn over additional documents ahead of a trial in a pay-for-delay multidistrict litigation involving the heartburn drug Nexium, saying direct-purchaser plaintiffs' supplement production request ignores recent court decisions and federal rules....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.